Effects of ligustrazine on expression of bone marrow heparan sulfates in syngeneic bone marrow transplantation mice

Abstract

To explore the effects of ligustrazine on bone marrow heparan sulfates (HS) expression in bone marrow transplantation (BMT) mice, the syngeneic BMT mice were orally given 2 mg ligustrazine twice a day. On the 7th, 10th, 14th, 18th day after BMT, peripheral blood cells and bone marrow nuclear cells (BMNC) were counted, and the expression levels of HS in bone marrow and on the stromal cell surfaces were detected by immunohistochemistry and flow cytometry assay respectively. In ligustrazine-treated group, the white blood cells (WBC) and BMNC on the 7th, 10th, 14th, 18th day and platelets (PLT) on the 7th, 10th day were all significantly more than those in control group (P<0.05). The bone marrow HS expression levels in ligustrazine-treated group were higher than those in control group (P<0.05) on the 7th, 10th, 14th, 18th day. However, the HS expression levels on the stromal cell surfaces showed no significant difference between the two groups on the 18th day (P>0.05). It was concluded that ligustrazine could up-regulate HS expression in bone marrow, which might be one of the mechanisms contributing to ligustrazine promoting hematopoietic reconstitution after BMT.

Keywords

bone marrow transplantation / hematopoietic reconstitution / heparan sulfates / ligustrazine

References

[1] GuptaP, OegemaT R, BraizilJ J, et al.. Structurally specific heparan sulfates support primitive human hematopoiesis by formation of a multimolecular stem cell niche. Blood, 1998, 92: 4641-4641 Braizil or Brazil)

[2] HanZ C, BellucciS, ShenZ X, et al.. Glycosamino-glycans enhance megakaryocytopoiesis by modifying the activities of hematopoietic growth regulators. J Cell Physiol, 1996, 168: 97-97

[3] BorghesiL A, YamashitaY, KincadeP W. Heparan sulfate proteoglycans mediate interleukin-7-dependent B lymphopoiesis. Blood, 1999, 93: 140-140

[4] GuptaP, OegemaT R, BrazilJ J, et al.. Human LTC-IC can be maintained for at least 5 weeks in vitro when interleukin-3 and a single chemokine are combined with O-sulfated heparan sulfates: requirement for optimal binding interactions of heparan sulfate with early-acting cytokines and matrix proteins. Blood, 2000, 95: 147-147

[5] BernfieldP N. Specificities of heparan sulphate proteoglycans in developmental processes. Nature, 2000, 404: 725-725